Biofrontera Inc (NASDAQ:BFRI) is a US based Bio-Technological subsidiary who develop treatments for dermatological conditions, in particular diseases caused primarily by exposure to sunlight. The German parent company, Biofrontera AG, chose to finance its US subsidiary via a IPO on the NASDAQ. The IPO was completed on 28 October 2021, raising $18 Million pricing each …
BFRI Stock: The Hype Around Biofrontera Stock Explained Read More »
Novavax Stock (NASDAQ: NVAX) is charging into 2022 with multiple potential catalysts including its final submission of clinical data to the US FDA. The outbreak of the Omicron Variant has reignited investor interests in Bio-Techs that are yet to receive approval from the US FDA and may have benefits not attainable from available vaccines. NVAX …
Novavax Stock (NASDAQ: NVAX) is a clinical example of a Bio-Tech success story for investors as COVID-19 grippled the world in March 2020. Since then, NVAX stock has returned investors over 1,600% reaching heights of $331 a share in February 2021. Since then, the stock has halved as Pfiser and Moderna, among others obtained an EUA …
Novavax Stock News: B. Riley Reaffirms a $305 Price Target Read More »
Krystal Biotech Stock (NASDAQ:KRYS) skyrocketed yesterday following an announcement on the companies Phase 3 trial data. Krystal Biotech was able to meet its primary and secondary endpoints in its latest trial targeting dystrophic Epidermolysis Bullosa (dystrophic EB). The companies topical gene therapy, Vyjuvek was able to demonstrate significant results in durable wound healing for patients …
KRYS Stock: Why this Wallstreet analyst set a $124 target on Krystal Biotech Read More »
Ocugen Inc (NASDAQ: OCGN) is a US based biopharmaceutical company which has primarily focused its research on developing a cure for blindness disease. However last year, Ocugen shifted their efforts towards distributing Covaxin, a COVID-19 vaccine developed by their Indian partner Bharat Biotech. Ocugen currently have the rights to distribute Covaxin in the US and …
What the WHO approval for Covaxin means for Ocugen stock Read More »
McKesson stock (NYSE: MCK) hit a 3-month high in the pre-market trading session on Tuesday, November 2, after announcing solid earnings and revenue for its fiscal second quarter. The company attributed the results to widening growth in the U.S. Pharmaceutical segment. The Texas-based distributor of medical supplies reported adjusted earnings of $6.15 per share, crushing …
Here’s why McKesson stock is trading higher on heavy volume Read More »
Ocugen stock (NASDAQ: OCGN) has been given a boost from Wallstreet over the past week after the company submitted an Investigational New Drug application with the U.S FDA to evaluate the COVID-19 vaccine candidate, Covaxin. The IND application caught the attention of Noble Financial analyst, Robert LeBoyer who reiterated the firms coverage on Ocugen sticking …
Ocugen stock price target reiterated at $15 by Noble Financial Read More »
UnitedHealth Group Inc. (NYSE: UNH) is a well-known health insurer, offering health care benefits to millions of clients, primarily in the U.S. UNH stock recently caught investors’ attention after the company delivered impressive profit and sales for the third quarter. Here’s why United Health stock is back in the spotlight with multiple Wallstreet institutions boosting their …
Here’s why United Health stock is back in the spotlight Read More »
Ocugen Inc (NASDAQ: OCGN) is a US based biopharmaceutical company which has primarily focused its research on developing a cure for blindness disease. However last year, Ocugen shifted their efforts towards distributing Covaxin, a COVID-19 vaccine developed by their Indian partner Bharat Biotech. Ocugen currently have the rights to distribute Covaxin in the US and Canada, …
Ocugen stock gains momentum ahead of WHO vaccine decision Read More »
Xenon Pharmaceuticals Inc (NASDAQ: XENE) stock has reached new heights after announcing promising trial results for its drug XEN1101 in the treatment for adult patients with focal epilepsy. The promising data rang bells on Wallstreet, with investors sending the stock 101.92% higher. Investors may be wondering if the stock is now overvalued with such a large …
XENE stock receives a $50 price target from Wallstreet analyst Read More »